{"id":163943,"date":"2025-03-26T17:07:00","date_gmt":"2025-03-26T17:07:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/"},"modified":"2025-03-26T17:07:00","modified_gmt":"2025-03-26T17:07:00","slug":"atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/","title":{"rendered":"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques"},"content":{"rendered":"\n<p>Ce mois-ci, Vaincre la c\u00e9cit\u00e9 Canada partage les derni\u00e8res avanc\u00e9es de deux essais cliniques portant sur des traitements potentiels de l\u2013atrophie g\u00e9ographique (AG), une forme avanc\u00e9e de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2013\u00e2ge (DMLA) s\u00e8che. \u00c0 ce jour, aucun traitement n\u2013a \u00e9t\u00e9 approuv\u00e9 au Canada pour cette pathologie.<\/p>\n\n\n\n<p>Alkeus a d\u00e9voil\u00e9 les r\u00e9sultats de son \u00e9tude de phase 3 Saga portant sur le gildeuretinol ac\u00e9tate (ALK-001), un m\u00e9dicament oral destin\u00e9 aux patients atteints d\u2013AG. Les r\u00e9sultats indiquent une r\u00e9duction de la progression des l\u00e9sions chez les patients sous traitement quotidien, comparativement \u00e0 ceux sous placebo. Cependant, la diff\u00e9rence observ\u00e9e n\u2013est pas statistiquement significative. Malgr\u00e9 cela, Alkeus demeure optimiste, soulignant qu\u2013il s\u2013agit du premier traitement oral \u00e0 d\u00e9montrer un impact sur l\u2013AG. L\u2013entreprise pr\u00e9voit d\u2013engager des discussions avec les agences de r\u00e9glementation, notamment la FDA, afin d\u2013\u00e9valuer les possibilit\u00e9s de mise \u00e0 disposition du traitement aux patients.<\/p>\n\n\n\n<p>De son c\u00f4t\u00e9, Galimedix a annonc\u00e9 le lancement de l\u2013essai clinique de phase 2 eDREAM, qui \u00e9valuera l\u2013efficacit\u00e9 d\u2013un collyre (GAL-101) contre l\u2013AG. Cette \u00e9tude, men\u00e9e sur un \u00e9chantillon pouvant atteindre 110 patients, comparera l\u2013effet des gouttes GAL-101 \u00e0 celui d\u2013un placebo. Les chercheurs analyseront si le collyre ralentit la progression des l\u00e9sions d\u2013AG. Parall\u00e8lement, GAL-101 est \u00e9galement \u00e0 l\u2013\u00e9tude pour le traitement du glaucome et de la maladie d\u2013Alzheimer.<\/p>\n\n\n\n<p>Vous voulez voir plus d'articles comme celui-ci? <a href=\"https:\/\/optiknow.ca\/custom-forms\/subscribe-fr.html\" target=\"_blank\" rel=\"noreferrer noopener\">Cliquez ici<\/a> pour vous abonner \u00e0 notre magazine imprim\u00e9 GRATUIT et \u00e0 nos infolettres!<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vaincre la c\u00e9cit\u00e9 Canada partage les derni\u00e8res avanc\u00e9es de deux essais cliniques portant sur des traitements potentiels de l\u0092atrophie g\u00e9ographique (AG), une forme avanc\u00e9e de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u0092\u00e2ge (DMLA) s\u00e8che. \u00c0 ce jour, aucun traitement n\u0092a \u00e9t\u00e9 approuv\u00e9 au Canada pour cette pathologie.<\/p>\n","protected":false},"author":1,"featured_media":148583,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23924],"tags":[26355,26356,26357,26358,26359,26360,26361,26362,25239],"class_list":["post-163943","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vision-et-dernieres-recherches","tag-alk-001","tag-atrophie-geographique","tag-collyre-gal-101","tag-dmla-seche","tag-essais-cliniques-ag","tag-gal-101","tag-recherche-en-ophtalmologie","tag-traitement-de-la-degenerescence-maculaire","tag-vaincre-la-cecite-canada"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques - OptikNow\" \/>\n<meta property=\"og:description\" content=\"Vaincre la c\u00e9cit\u00e9 Canada partage les derni\u00e8res avanc\u00e9es de deux essais cliniques portant sur des traitements potentiels de l\u0092atrophie g\u00e9ographique (AG), une forme avanc\u00e9e de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u0092\u00e2ge (DMLA) s\u00e8che. \u00c0 ce jour, aucun traitement n\u0092a \u00e9t\u00e9 approuv\u00e9 au Canada pour cette pathologie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T17:07:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/Research_FBC-Optik-logos-810x338-v2-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"810\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques\",\"datePublished\":\"2025-03-26T17:07:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/\"},\"wordCount\":282,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Research_FBC-Optik-logos-810x338-v2-1.jpg\",\"keywords\":[\"ALK-001\",\"atrophie g\u00e9ographique\",\"collyre GAL-101\",\"DMLA s\u00e8che\",\"essais cliniques AG\",\"GAL-101\",\"recherche en ophtalmologie\",\"traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire\",\"Vaincre la c\u00e9cit\u00e9 Canada\"],\"articleSection\":[\"Sciences de la vision et derni\u00e8res recherches\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/\",\"name\":\"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Research_FBC-Optik-logos-810x338-v2-1.jpg\",\"datePublished\":\"2025-03-26T17:07:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Research_FBC-Optik-logos-810x338-v2-1.jpg\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Research_FBC-Optik-logos-810x338-v2-1.jpg\",\"width\":810,\"height\":338,\"caption\":\"Fighting Blindness Canada\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2025\\\/03\\\/26\\\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques - OptikNow","og_description":"Vaincre la c\u00e9cit\u00e9 Canada partage les derni\u00e8res avanc\u00e9es de deux essais cliniques portant sur des traitements potentiels de l\u0092atrophie g\u00e9ographique (AG), une forme avanc\u00e9e de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u0092\u00e2ge (DMLA) s\u00e8che. \u00c0 ce jour, aucun traitement n\u0092a \u00e9t\u00e9 approuv\u00e9 au Canada pour cette pathologie.","og_url":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/","og_site_name":"OptikNow","article_published_time":"2025-03-26T17:07:00+00:00","og_image":[{"width":810,"height":338,"url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/Research_FBC-Optik-logos-810x338-v2-1.jpg","type":"image\/jpeg"}],"author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques","datePublished":"2025-03-26T17:07:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/"},"wordCount":282,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/Research_FBC-Optik-logos-810x338-v2-1.jpg","keywords":["ALK-001","atrophie g\u00e9ographique","collyre GAL-101","DMLA s\u00e8che","essais cliniques AG","GAL-101","recherche en ophtalmologie","traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire","Vaincre la c\u00e9cit\u00e9 Canada"],"articleSection":["Sciences de la vision et derni\u00e8res recherches"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/","url":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/","name":"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#primaryimage"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/Research_FBC-Optik-logos-810x338-v2-1.jpg","datePublished":"2025-03-26T17:07:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#primaryimage","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/Research_FBC-Optik-logos-810x338-v2-1.jpg","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/Research_FBC-Optik-logos-810x338-v2-1.jpg","width":810,"height":338,"caption":"Fighting Blindness Canada"},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2025\/03\/26\/atrophie-geographique-mise-a-jour-sur-deux-essais-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Atrophie g\u00e9ographique : mise \u00e0 jour sur deux essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/163943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=163943"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/163943\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media\/148583"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=163943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=163943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=163943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}